MIRM

Mirum Pharmaceuticals (MIRM) is the lead sponsor of 11 active clinical trials listed on ClinicalTrials.gov^[4], including 5 Phase 3^[1], 5 Phase 2^[2], 1 Phase 4^[3].

Trial NCT06553768^[5] evaluates Maralixibat in Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) with a target enrollment of 90 participants. Trial NCT07454837^[6] evaluates Brelovitug (BJT-778) in Chronic Hepatitis D with a target enrollment of 120 participants. Trial NCT07200908^[7] evaluates Brelovitug 300 mg in Chronic Hepatitis D Infection with a target enrollment of 172 participants.

MIRM has 6 Form 4 insider filings recorded at the SEC in the past 30 days^[8].